CoChat

Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications

Open access
Taléns-Visconti, Raquel, de Julián-Ortiz, Jesus Vicente, Vila-Busó, Ofelia, Diez-Sales, Octavio, Nácher, Amparo · 2023 · Pharmaceutics

The DOI matches its Crossref record; 71 of the 73 references it cites were found in a registry or an index.

Abstract

Alzheimer-type dementia (ATD) treatments face limitations in crossing the blood–brain barrier and systemic adverse effects. Intranasal administration offers a direct route to the brain via the nasal cavity’s olfactory and trigeminal pathways. However, nasal physiology can hinder drug absorption and limit bioavailability. Therefore, the physicochemical characteristics of formulations must be optimized by means of technological strategies. Among the strategies that have been explored, lipid-based nanosystems, particularly nanostructured lipid carriers, are promising in preclinical investigations with minimal toxicity and therapeutic efficacy due to their ability to overcome challenges associated with other nanocarriers. We review the studies of nanostructured lipid carriers for intranasal administration in the treatment of ATD. Currently, no drugs for intranasal administration in ATD have marketing approval, with only three candidates, insulin, rivastigmine and APH-1105, being clinically investigated. Further studies with different candidates will eventually confirm the potential of the intranasal route of administration in the treatment of ATD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics15051399

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 7 Innervation of the trigeminal nerve in the nasal cavity [39].
Figure 7 Innervation of the trigeminal nerve in the nasal cavity [39].CC BY · PubMed Central
Figure 1 Main differences between a healthy brain and a brain with Alzheimer-type dementias.
Figure 1 Main differences between a healthy brain and a brain with Alzheimer-type dementias.CC BY · PubMed Central
Figure 2 Structure of the blood–brain barrier.
Figure 2 Structure of the blood–brain barrier.CC BY · PubMed Central
Figure 3 (a) Anatomy of the nasal cavity, adapted from [32]. (b) Schematic representation of the olfactory region, adapted from [33].
Figure 3 (a) Anatomy of the nasal cavity, adapted from [32]. (b) Schematic representation of the olfactory region, adapted from [33].CC BY · PubMed Central
Figure 4 Factors affecting absorption through the nasal route [34].
Figure 4 Factors affecting absorption through the nasal route [34].CC BY · PubMed Central
Figure 5 Mechanisms of drug absorption across the nasal epithelium [32].
Figure 5 Mechanisms of drug absorption across the nasal epithelium [32].CC BY · PubMed Central
Figure 6 Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].
Figure 6 Intranasal transport of drugs through the olfactory route to the CNS by intracellular and extracellular routes [36].CC BY · PubMed Central
Figure 8 Schematic representation of the structure of the nasal cavity and the mechanisms of drug absorption through the nasal mucosa to the brain. (A) Direct absorption mechanism through olfactory nerve and trigeminal route. (B) Indirect absorption mechanism by systemic route [42].
Figure 8 Schematic representation of the structure of the nasal cavity and the mechanisms of drug absorption through the nasal mucosa to the brain. (A) Direct absorption mechanism through olfactory nerve and trigeminal route. (B) Indirect absorption mechanism by systemic route [42].CC BY · PubMed Central
Figure 9 Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].
Figure 9 Lipid-based nanocarriers that have been explored for drug access to the brain from the nasal route [62].CC BY · PubMed Central
Figure 10 Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].
Figure 10 Main differences between solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLCs) [66].CC BY · PubMed Central
Figure 11 Current status of the investigation of nasal therapies for Alzheimer-type dementia.
Figure 11 Current status of the investigation of nasal therapies for Alzheimer-type dementia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Rajput, 2018, Fabrication of an ion-sensitive in situ gel loaded with nanostructured lipid carrier for nose to brain delivery of donepezil, Asian J. Pharm., 12, 293

Cited by

See all 59

Metadata

Authors
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A.
Affiliations
  • Department of Pharmacy and Pharmaceutical Technology and Parasitology, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
  • Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicent Andrés Estellés s/n, 46100 Valencia, Spain
  • Universitat de València (ES)
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2023-05-03
Volume
15
Issue
5
Pages
1399
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4378516181
Cited by
59
References
73
Citations by year
2026: 14 · 2025: 20 · 2024: 19 · 2023: 6
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
intranasal administration, Alzheimer-type dementia, nanostructured lipid carriers, lipid-based nanosystems, blood-brain barrier, intranasal drug delivery, drug bioavailability, nanocarriers, rivastigmine, insulin, Alzheimer's disease treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.